▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2462 by analyst upside · 2026-06-27
IMVT
Immunovant, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+17.8%
implied upside to consensus target
Current Price $38.85
Consensus Target $45.76
Bull Target $66.0
Bear Target $24.0
Analysts Covering 17
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
10
Hold
5
Sell
0
52-Week Low $14.32
52-Week High $39.28
YTD Return +49.9%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E -15.9x
EPS (TTM) $-2.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $14.32
52-Week High $39.28
Current Price $38.85
Bear Target $24.0
Bull Target $66.0
● Now $38.85 ● Target $45.76
TRADING DATA
Avg Volume 1.9M
YTD Return +49.9%
Analyst Count 17
Consensus Buy
Upside to Target +17.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Immunovant, Inc. (IMVT) is currently trading at $38.85 with a Wall Street consensus price target of $45.76, implying potential upside of 17.8% over the next 12 months. 17 analysts currently cover IMVT, with a consensus rating of Buy — 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $24.0.

IMVT operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 49.9% year-to-date and is currently trading near the upper end of its 52-week range of $14.32 – $39.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

QGEN +11.6%
Qiagen N.V.
$8B · P/E 20.1x · Buy
ATR +27.3%
AptarGroup, Inc.
$8B · P/E 21.6x · Buy
HALO +11.9%
Halozyme Therapeutics, Inc.
$9B · P/E 26.3x · Buy
PACS +18.6%
PACS Group, Inc.
$7B · P/E 27.0x · Buy
HQY +30.6%
HealthEquity, Inc.
$7B · P/E 31.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IMVT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim — Reiterated
Buy → Buy 2026-05-26 62% win rate (8 calls)
Truist Securities — Reiterated
Hold → Hold 2026-05-22 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-05-21 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-21 31% win rate (48 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2026-04-15 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-02-10 31% win rate (48 calls)
Guggenheim — Reiterated
Buy → Buy 2026-02-09 62% win rate (8 calls)
Truist Securities — Reiterated
Hold → Hold 2026-01-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →